Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
Purpose: To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Materials and Methods: Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of grea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Association
2020-07-01
|
| Series: | Investigative and Clinical Urology |
| Subjects: | |
| Online Access: | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-419.pdf |
| _version_ | 1818369760838025216 |
|---|---|
| author | Se Yun Kwon Dong Jin Park Young Jin Seo Kyung Seop Lee |
| author_facet | Se Yun Kwon Dong Jin Park Young Jin Seo Kyung Seop Lee |
| author_sort | Se Yun Kwon |
| collection | DOAJ |
| description | Purpose: To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Materials and Methods: Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of greater than 3 points, were initially enrolled. One group added any alpha-adrenoreceptor blocker with mirabegron 50 mg (n=39; the mirabegron group) and the other group received alpha-adrenoreceptor blocker only (n=19; the control group) for 8 weeks. Results: In the control group, mean total IPSS decreased from 15.7 to 13.1 (p=0.298) and in mirabegron group, mean total IPSS decreased from 19.4 to 16.5 (p=0.024). Mean storage symptom scores reduced in the control and mirabegron groups from 8.5 to 7.9 (p=0.584) and from 9.1 to 7.6 (p=0.015), respectively, and mean QoL scores from 3.7 to 3.1 (p=0.052) and 3.6 to 3.2 (p=0.027), respectively. Mean overall OABSS in the control and mirabegron groups reduced from 8.4 to 7.2 (p=0.173) and from 8.8 to 7.3, respectively (p=0.005); mean OABSS Q3 from 3.6 to 2.9 (p=0.073) and from 3.5 to 2.7 (p=0.002), respectively; and mean OABSS Q4 from 2.4 to 2.0 (p=0.306) and from 2.7 to 2.0 (p=0.016), respectively. The change of mean Qmax and PVR was insignificant in 2 groups. Conclusions: IPSS total scores, storage symptom scores, QoL, overall OABSS, OABSS Q3 and Q4 were more improved significantly by alpha-adrenoreceptor blocker with mirabegron 50 mg in BPH patients with persistent overactive symptoms. Mirabegron 50 mg addition is considered to patients with persistent storage symptoms after alpha-adrenoreceptor blocker. |
| first_indexed | 2024-12-13T23:28:58Z |
| format | Article |
| id | doaj.art-78deb42e1a5d4574a7c7d84863a2a973 |
| institution | Directory Open Access Journal |
| issn | 2466-0493 2466-054X |
| language | English |
| last_indexed | 2024-12-13T23:28:58Z |
| publishDate | 2020-07-01 |
| publisher | Korean Urological Association |
| record_format | Article |
| series | Investigative and Clinical Urology |
| spelling | doaj.art-78deb42e1a5d4574a7c7d84863a2a9732022-12-21T23:27:28ZengKorean Urological AssociationInvestigative and Clinical Urology2466-04932466-054X2020-07-0161441942410.4111/icu.2020.61.4.419Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective studySe Yun Kwon 0https://orcid.org/0000-0003-1147-8037Dong Jin Park 1https://orcid.org/0000-0003-1667-2146Young Jin Seo2https://orcid.org/0000-0002-9114-8363Kyung Seop Lee 3https://orcid.org/0000-0002-0554-4272Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.Purpose: To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Materials and Methods: Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of greater than 3 points, were initially enrolled. One group added any alpha-adrenoreceptor blocker with mirabegron 50 mg (n=39; the mirabegron group) and the other group received alpha-adrenoreceptor blocker only (n=19; the control group) for 8 weeks. Results: In the control group, mean total IPSS decreased from 15.7 to 13.1 (p=0.298) and in mirabegron group, mean total IPSS decreased from 19.4 to 16.5 (p=0.024). Mean storage symptom scores reduced in the control and mirabegron groups from 8.5 to 7.9 (p=0.584) and from 9.1 to 7.6 (p=0.015), respectively, and mean QoL scores from 3.7 to 3.1 (p=0.052) and 3.6 to 3.2 (p=0.027), respectively. Mean overall OABSS in the control and mirabegron groups reduced from 8.4 to 7.2 (p=0.173) and from 8.8 to 7.3, respectively (p=0.005); mean OABSS Q3 from 3.6 to 2.9 (p=0.073) and from 3.5 to 2.7 (p=0.002), respectively; and mean OABSS Q4 from 2.4 to 2.0 (p=0.306) and from 2.7 to 2.0 (p=0.016), respectively. The change of mean Qmax and PVR was insignificant in 2 groups. Conclusions: IPSS total scores, storage symptom scores, QoL, overall OABSS, OABSS Q3 and Q4 were more improved significantly by alpha-adrenoreceptor blocker with mirabegron 50 mg in BPH patients with persistent overactive symptoms. Mirabegron 50 mg addition is considered to patients with persistent storage symptoms after alpha-adrenoreceptor blocker.https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-419.pdfmirabegronprostatic hyperplasiaurinary bladderoveractive |
| spellingShingle | Se Yun Kwon Dong Jin Park Young Jin Seo Kyung Seop Lee Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study Investigative and Clinical Urology mirabegron prostatic hyperplasia urinary bladder overactive |
| title | Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study |
| title_full | Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study |
| title_fullStr | Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study |
| title_full_unstemmed | Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study |
| title_short | Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study |
| title_sort | efficacy of adding mirabegron to alpha adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms a prospective study |
| topic | mirabegron prostatic hyperplasia urinary bladder overactive |
| url | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-419.pdf |
| work_keys_str_mv | AT seyunkwon efficacyofaddingmirabegrontoalphaadrenoreceptorblockerinpatientswithbenignprostatichyperplasiawithpersistentoveractivebladdersymptomsaprospectivestudy AT dongjinpark efficacyofaddingmirabegrontoalphaadrenoreceptorblockerinpatientswithbenignprostatichyperplasiawithpersistentoveractivebladdersymptomsaprospectivestudy AT youngjinseo efficacyofaddingmirabegrontoalphaadrenoreceptorblockerinpatientswithbenignprostatichyperplasiawithpersistentoveractivebladdersymptomsaprospectivestudy AT kyungseoplee efficacyofaddingmirabegrontoalphaadrenoreceptorblockerinpatientswithbenignprostatichyperplasiawithpersistentoveractivebladdersymptomsaprospectivestudy |